

Last Updated July 2023

Original Research:

1. Ribeiro CM, Higgs MG, **Muhlebach MS**, Wolfgang MC, Borgatti M, Lampronti I, Cabrini G. Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators. *Int J of Molecular Sciences*. 2023 Mar 5;24(5):5010. doi: 10.3390/ijms24055010
2. De Vuyst RC, Jalazo E, Tsujimoto TM, Lin FC, Muenzer J, **Muhlebach MS**. Airway Findings in Patients with Hunter syndrome treated with Intravenous Idursulfase. *J Clin Med*. 2023 Jan 6;12(2):480. doi: 10.3390/jcm12020480. PMID: 36675409
3. Interventions for the eradication of meticillin-resistant *Staphylococcus aureus* (MRSA) in people with cystic fibrosis. Lo DK, Muhlebach MS, Smyth AR. *Cochrane Database Syst Rev*. 2022 Dec 13;12(12):CD009650. doi: 10.1002/14651858.CD009650.pub5. PMID: 36511181
4. Lu KY, Wagner NJ, Velez AZ, Ceppe A, Conlon BP, **Muhlebach MS**. Antibiotic Tolerance and Treatment Outcomes in Cystic Fibrosis Methicillin-Resistant *Staphylococcus aureus* Infections. *Microbiol Spectr*. 2022 Dec 15;e0406122. doi: 10.1128/spectrum.04061-22
5. Cunningham F, Caldwell E, Mayer-Hamblett N, Goss CH, **Muhlebach MS**. Eradication of early MRSA infection in cystic fibrosis: a novel study design for the STAR-ter trial. *ERJ Open Res*. 2022 Dec 5;8(4):00190-2022. doi: 10.1183/23120541.00190-2022. PMID: 36478917
6. Stoudemire W, Jiang X, Zhou JJ, Kosorok MR, Saiman L, **Muhlebach MS**. Predicting risk-adjusted incidence rates of methicillin-resistant *Staphylococcus Aureus* and *Pseudomonas Aeruginosa* in cystic fibrosis programs in the United States. *J Cyst Fibros*. 2022 Aug 10:S1569-1993(22)00639-7. doi: 10.1016/j.jcf.2022.08.002. Epub ahead of print. PMID: 35963814.
7. Batson BD, Zorn BT, Radicioni G, Livengood SS, Kumagai T, Dang H, Ceppe A, Clapp PW, Tunney M, Elborn JS, McElvaney NG, **Muhlebach MS**, Boucher RC, Tiemeyer M, Wolfgang MC, Kesimer M. Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions that Promotes Disease Persistence. *Am J Respir Cell Mol Biol*. 2022 Aug;67(2):253-265. doi: 10.1165/rcmb.2021-0359OC. PMID: 35486871; PMCID: PMC9348562.
8. Markovetz MR, Garbarine IC, Morrison CB, Kissner WJ, Seim I, Forest MG, Papanikolas MJ, Freeman R, Ceppe A, Ghio A, Alexis NE, Stick SM, Ehre C, Boucher RC, Esther CR, **Muhlebach MS**, Hill DB. Mucus and mucus flake composition and abundance reflect inflammatory and infection status in cystic fibrosis. *J Cyst Fibros*. 2022 Apr 15:S1569-1993(22)00097-2. doi: 10.1016/j.jcf.2022.04.008. Epub ahead of print. PMID: 35437233.
9. **Muhlebach, M.S.** Jiang, X; Kosorok, MR; Eili Y. Klein, EY; Saiman L. Longitudinal changes and regional variation of incident infection rates at cystic fibrosis centers, United States 2010-2016 *J Cyst Fibros*. 2021 Aug 26: S1569-1993(21)01350-3. doi: 0.1016/j.jcf.2021.08.009.
10. Saiman, L; Zhou JJ; Shah, KS; Jiang, X; Stoudemire, W; Kosorok, MR **Muhlebach, MS.** and CF IP&C Study Group. Barriers implementing Infection Prevention & Control experienced by healthcare workers, People with CF and parents. *J Cyst Fibros*. 2021 Sep 11: S1569-1993(21)01307-2. doi: 10.1016/j.jcf.2021.07.009
11. Gross JE, McCown MY, Okorie CUA, Bishay LC, Dy FJ, Astudillo CL, **Muhlebach MS**, Abu-Nassar S, Chen DY, Hossain N, Wang R, Klouda T, Martiniano SL, Lenhart-Pendergrass P, Kirkby S, Ortenberg R, McSparron JI, Wang T, Hayes MM, Çoruh B. *ATS Core Curriculum 2021*. *Pediatric*

Pulmonary Medicine: Pulmonary Infections. *ATS Sch.* 2021 Sep 8;2(3):452-467. doi: 10.34197/ats-scholar.2021-0034RE. PMID: 34667993; PMCID: PMC8518607.

12. **Muhlebach MS**, Cunningham F, LiPuma JJ, Zhou JJ, Saiman L. Impact of the SARS-CoV2 pandemic on cystic fibrosis centers and care – Survey results from U.S. centers. *ERJ Open*, 7 (4) 00249-2021; DOI: 10.1183/23120541.00249-2021
13. Gilpin D, Hoffman LR, Ceppe A, **Muhlebach MS**. Phenotypic characteristics of incident and chronic MRSA isolates in cystic fibrosis. *J Cyst Fibros.* 2021 Jun 5:S1569-1993(21)00168-5. doi: 10.1016/j.jcf.2021.05.015.
14. Sagel SD, Wagner, BD., Ziady, A., Kelley, T., Clancy, JP, Narvaez-Rivas, M., Pilewski, J., Joseloff, E., Sha, W., Zelnick, L, Setchell, KDR., Heltsh, SL., **Muhlebach, MS**. Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity. *J Cyst Fibros.* 2020 Jul;19(4):632-640. doi: 10.1016/j.jcf.2019.12.007. PMID: 31870630
15. Bullington W. Smyth, A; Drevinek, P; Sarah, H; Waters, V; Bell, S; VanDevanter, D; Flume, PA; Saiman, L; Elborn, JS; **Muhlebach, MS**. Concerns by care providers and people with CF about antimicrobial resistance. *J of Cyst Fibros.* 2020 Jun 17;S1569-1993(20)30159-4. doi: 10.1016/j.jcf.2020.05.009 PMID: 32563724
16. Cogen, JD*1, Kahl BC, Maples, H., McColley SA, Roberts, JA, Winthrop, K; Morris, A; Holmes, A; Flume, PA, VanDevanter, D, Waters, V; **Muhlebach, MS**, Elborn, JS, Saiman, L., Bell, SC on behalf of the Antimicrobial Resistance International Working Group in Cystic Fibrosis. Finding the relevance of antimicrobial stewardship for cystic fibrosis. *J Cyst Fibros.* 2020 Jul;19(4):511-520. doi: 10.1016/j.jcf.2020.02.012. PMID: 32122785
17. Ghosh A, Coakley RD, Ghio AJ, **Muhlebach MS**, Esther CR Jr, Alexis NE, Tarran R. Chronic E-Cigarette Use Increases Neutrophil Elastase and Matrix Metalloprotease Levels in the Lung. *Am J Respir Crit Care Med.* 2019 Aug 7. doi: 10.1164/rccm.201903-0615OC. PMID: 31390877
18. **Muhlebach MS**, Sha W, MacIntosh B, Kelley TJ, Muenzer J. Metabonomics reveals altered metabolites related to inflammation and energy utilization at recovery of cystic fibrosis lung exacerbation. *Metabolism Open.* <https://doi.org/10.1016/j.metop.2019.100010>
19. Esther CR.* , **Muhlebach MS***, Ehre C, Hill DB, Wolfgang MC, Kesimer M, Ramsey KA, Markovetz MR, Garbarine IC, Forest G, Seim I, Zorn B, Morrison CB, Delion MF, Turkovic L, Ranganathan S, Stick SM†, Boucher RC†. * joint first authors; †joint senior authors. Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis. *Sci Transl Med.* 2019 Apr 3;11(486). pii: eav3488. doi: 10.1126/scitranslmed.aav3488.
20. Sherrard LJ*, Einarsson GG*, Johnston E, O'Neill K, McIlreavey L, McGrath SJ, Gilpin DF, Downey DG, Reid A, McElvaney GN, Boucher RC, **Muhlebach MS**, Elborn JS†, Tunney MM†. Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis. *J Cyst Fibros.* 2019 Mar 21. pii: S1569-1993(19)30052-9. doi: 10.1016/j.jcf.2019.02.012
21. Stoudemire W, **Muhlebach, MS**, Zhou JJ, Maykowski P, Jiang X, Kosorok MR Saiman L. Cystic fibrosis program characteristics associated with adoption of the 2013 Infection Prevention and Control Recommendations. *American Journal of Infection Control.* 2019 Apr 26. pii: S0196-6553(19)30175-0. doi: 10.1016/j.ajic.2019.03.015
22. Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, **Muhlebach MS**, Gilpin DF, Schneiders T, Stuart Elborn J, Tunney MM. Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in *Prevotella* isolated from cystic fibrosis (CF) and non-CF patients. *J Antimicrob Chemother.* 2018 Nov 1;73(11):3218. doi: 10.1093/jac/dky313. PMID: 30351435

23. **Muhlebach MS**, Hatch JE, Einarsson GG, McGrath SJ, Gilpin DF, Gillian Lavelle, Mirkovic B, McNally P, Gotman N, Thomas SD, Wolfgang MC, Gilligan PH, McElvaney NG, Elborn JS, Boucher RC, Tunney MM. Cultured lower airway anaerobic and aerobic microbial communities in CF vary by age. *Eur Respir J*. 2018 Jul 11;52(1). doi: 10.1183/13993003.00242-2018. PMID: 29946004
24. Lo DKH, **Muhlebach MS**, Smyth AR. Interventions for the eradication of meticillin-resistant *Staphylococcus aureus* (MRSA) in people with cystic fibrosis. *Cochrane Review*. 2018;7. DOI: 10.1002/14651858.CD009650.pub4
25. Saiman L, Zhou JJ, Jiang X, Kosorok MR, **Muhlebach MS**. Surveying Cystic Fibrosis Care Centers to Assess Adoption of Infection Prevention and Control Recommendations. *Infect Control Hosp Epidemiol*. 2018 Jun;39(6):647-651. doi: 10.1017/ice.2018.72
26. Sanders CD*, Guimbellot JS*, **Muhlebach MS**, Lin FC, Gilligan P, Esther Jr.CR. Tracheostomy infections in children: epidemiology and clinical outcomes *Ped Pulmonol*. 2018 Jul 3. doi: 10.1002/ppul.24071. PMID: 29968973
27. **Muhlebach MS**, Zorn BT, Esther CR, Hatch JE., Murray C, Turkovic L, Lassmann T, Ranganathan S, Wolfgang MC, Boucher RC, Stick SM, for AREST CF. Progression of the bronchoalveolar lavage microbiome and disease markers in pre-school children with CF. *PLoS Pathog*. 2018 Jan 18;14(1):e1006798. doi: 10.1371/journal.ppat.1006798.
28. †**Muhlebach MS**, †Clancy JP, Heltshe SL, Ziady A, Kelley T, Accurso F, Pilewski J, Mayer-Hamblett N, Joseloff E, Sagel SD. Biomarkers for cystic fibrosis drug development. *J Cystic Fibrosis* 2016;15(6): 714-723 doi.org/10.1016/j.jcf.2016.10.009
29. **Muhlebach MS**, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N, Zemanick ET, Hoover WC, VanDalfsen JM, Campbell P, Goss CH; STAR-too study team. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. *Thorax*. 2017 72(4):318-326. doi: 10.1136/thoraxjnl-2016-208949. PMID 27852955
30. **Muhlebach MS**, JP. Clancy, JP., Heltshe, SL, Ziady A, Kelley T, Pilewski J, Mayer-Hamblett N., Joseloff, E., Sagel, SD. Biomarkers for Cystic Fibrosis Drug Development. *J Cyst Fibros*. 2016 Nov;15(6):714-723. doi: 10.1016/j.jcf.2016.10.009. PMID: 28215711
31. Wooten, WI, III, **Muhlebach, MS**; Loughlin CE, Muenzer, J, Vaughn, BV. Progression of Polysomnographic Abnormalities in Mucopolidosis II (I-Cell Disease). *Journal of Clinical Sleep Medicine (JCSM)*. Accepted Aug. 2016
32. Esther CR Jr., Turkovic L, Rosenow T, **Muhlebach MS**, Boucher, RC, Stick., SM. Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis. *Eur Respir J*. 2016 Dec;48(6):1612-1621. PubMed PMID: 27836957.
33. Monogue,ML, Pettit,RS, **Muhlebach, MS**, Cies,J, Nicolau,DP, Kuti, JL. Population Pharmacokinetics and Safety of Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. *Antimicrob Agents Chemother*. 2016 Aug 22. pii: AAC.01566-16. PMID: 27550351
34. Sherrard LJ, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, **Muhlebach MS**, Gilpin DF, Elborn JS, Tunney MM. Production of extended-spectrum β -lactamases and the potential indirect pathogenic role of *Prevotella* isolates from the cystic fibrosis respiratory microbiota. *Int J Antimicrob Agents*. 2016 Feb;47(2):140-5. doi: 10.1016/j.ijantimicag.2015. PMID: 26774156

35. Pettit,RS, Neu,N, Jeffrey J. Cies,JJ, Lapin,C, **Muhlebach,MS**, Novak,KJ, Nguyen,ST, Saiman,L, Nicolau,DP, Kuti, JL. Population Pharmacokinetics of Meropenem Administered as a Prolonged-Infusion in Children with Cystic Fibrosis. *J Antimicrob Chemother.* 2016 Jan;71(1):189-95. doi: 10.1093/jac/dkv289. PMID: 26416780
36. Mirković, B. Murray,MA, Lavelle,GM, Molloy,K, Azim,AA, Gunaratnam,C, Healy, F, Slattery, D, McNally,P, Hatch, J, Wolfgang, M, Tunney,MM, **Muhlebach,MS**, Devery, R, Greene,CM, McElvaney, NG. Short-chain Fatty Acids Cause an IL-8 Response in Cystic Fibrosis Airways via Increased GPR41. *Am J Respir Crit Care Med.* 2015 Dec 1;192(11):1314-24. doi: 10.1164/rccm.201505-0943OC. PMID: 26266556
37. Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP. Microbiological activity of ceftolozane/tazobactam, ceftazidime,meropenem, and piperacillin/tazobactam against *Pseudomonas aeruginosa* isolated from children with cystic fibrosis. *Diagnostic Microbiology and Infectious Disease.* 2015 (83) 53–55 PMID: 26003469
38. **Muhlebach MS**, Heltshe SL, Popowitch EB, Miller MB, Thompson V, Kloster M, Ferkol T, Hoover WC, Schechter MS, Saiman L, and the STAR-CF Study Team. Factors and Outcomes Associated with Different MRSA Types in Children with Cystic Fibrosis. *Ann Am Thorac Soc.* 2015 Jun;12(6):864-71. doi: 10.1513/AnnalsATS.201412-596OC. PMID: 25745825
39. Heltshe, SL. Saiman L, Popowitch EB, Miller MB, Klosters M, Thompson V, Ferkol TW, Hoover WC, Schechter MS, **Muhlebach MS**. For the STAR-CF Study group. Outcomes and Treatment of chronic MRSA differs by SCCmec type in children with Cystic Fibrosis. *J Pediatric Infect Dis Soc.* 2015 Sep;4(3):225-31. doi: 10.1093/jpids/piu048. PMID: 26336603
40. **Muhlebach MS**, Sha W. Lessons learned from metabolomics in cystic fibrosis. *Mol Cell Pediatr.* 2015 Dec;2(1):9. doi: 10.1186/s40348-015-0020-8.
41. Sherrard, L; Graham, K; McGrath, S; McIlreavey, L; Hatch, J; **Muhlebach, M**; Wolfgang, M; Gilpin, D; Elborn, S; Schneiders, T; Tunney, M; Schaible, B. Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in *Prevotella* isolated from cystic fibrosis (CF) and non-CF patients. *J Antimicrob Chemother.* 2014 Oct;69(10):2690-8. doi: 10.1093/jac/dku192 PMID: 24917582
42. Lazrak A, Jurkavanete A, Ness E, Zhang S, Woodworth BA, **Muhlebach M**, Stober V, Lim YP, Garantziotis S, Matalon S. Inter- α -Inhibitor Blocks ENaC Activation and Decreases Nasal Potential Differences in DF508 Mice. *American Journal of Cell and Molecular Biology.* *Am J Respir Cell Mol Biol.* 2014 May;50(5):953-62. doi: 10.1165/rcmb.2013-0215OC.
43. Sherrard LJ, Graham KA, McGrath SJ, McIlreavey L, Hatch J, **Muhlebach MS**, Wolfgang MC, Gilpin DF, Elborn JS, Schneiders T, Tunney MM. *J Antimicrob Chemother.* 2013 May 21. Antibiotic resistance in *Prevotella* species isolated from patients with cystic fibrosis. *Journal Antimicrobial Chemotherapy.* 2013 PMID: 23696621
44. Joseloff E, Sha W, Bell SC, Wetmore DR, Lawton KA, Milburn MV, Ryals JA, Guo L, **Muhlebach MS**. Serum metabolomics indicate altered cellular energy metabolism in children with cystic fibrosis. *Ped Pulm. Pediatr Pulmonol.* 2014 49:463–472 doi: 10.1002/ppul.22859
45. Champion, EA, Miller MB, Popowitch EP, Saiman L, **Muhlebach MS**. for the STAR-CF Study Team. *Ped Pulm. Antimicrobial Susceptibility and Staphylococcal Chromosomal Cassette Type of MRSA in Cystic Fibrosis. Pediatr Pulmonol.* 2013.June 14 doi: 10.1002/ppul.22815

46. Lo DK, Hurley MN, **Muhlebach MS**, Smyth AR. Interventions for the eradication of methicillin-resistant *Staphylococcus aureus* (MRSA) in people with cystic fibrosis. *Cochrane Database Syst Rev*. 2013 Feb 28;2:CD009650
47. Ghio A, Roggli VL, Soukup JM, Richards JH, Randell SH, **Muhlebach MS**. Iron accumulates in the lavage and explanted lungs of cystic fibrosis patients *J Cyst Fibrosis*. 2013 Jul;12(4):390-8 doi:pii: S1569-1993(12)00202-0
48. Wooten WI, Muenzer J, Vaughn BV, **Muhlebach MS**. Relationship of Sleep to Pulmonary Function in Mucopolysaccharidosis II. *The Journal of Pediatrics*. *J Pediatr*. 2013 Jun;162(6):1210-1215 doi: 10.1002/ppul.22629
49. **Muhlebach MS**, Shaffer CB, Georges L, Abode K, Muenzer J. Bronchoscopy and airway management in patients with muco-polysaccharidoses (MPS). *Pediatr Pulmonol*. 2013 Jun;48(6):601-7. doi: 10.1002/ppul.22629
50. Goss CH, **Muhlebach MS**. *S. aureus* and MRSA in Cystic Fibrosis. *J Cystic Fibrosis* 2011 10(5):298-306
51. Keel RA, Schaeflein A, Kloft C, Pope JS, Knauff RF, **Muhlebach M**, Nicolau DP, Kuti JL. Pharmacokinetics of Intravenous and Oral Linezolid in Adults with Cystic Fibrosis. *Antimicrob Agents Chemother*. 2011;55(7):3393-3398. PMID: 21518837
52. **Muhlebach MS**, Miller M, Lavange LM, Mayhew G, Goodrich JS, Miller MB. Treatment intensity and characteristics of MRSA infection in CF. *J Cystic Fibrosis* 2011;10(3):201-206
53. Harris WT., **Muhlebach MS.**, Oster RA., Knowles MR., Clancy JP., Noah TL. Plasma TGF- β 1 in pediatric cystic fibrosis: Potential biomarker of lung disease severity and response to therapy. *Ped Pulm*. 2011; 46(7):688-95
54. Tunney MM, Klem E, Moriarty TF, Gilpin DF, McGrath SJ, **Muhlebach MS**, Boucher R, McDowell A, Elborn JS, Cardwell C, Patrick S, Moore J, Doering G, Wolfgang MC. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in cystic fibrosis patients. *Thorax* 2011;66(7):579-584
55. Lu KD, Engmann C, Moya F, **Muhlebach M**. Cystic Fibrosis in premature infants. *J. Perinatology*. 2011;31:504–506.
56. Harris WT, **Muhlebach MS**, Oster RA., Knowles MR, Noah TL. Transforming growth factor-beta 1 in bronchoalveolar lavage fluid from children with cystic fibrosis. *Ped Pulm*. 2009;44:1057-1064
57. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, **Muhlebach MS**, Wolfgang M, Boucher RC, Gilpin DF, McDowell A, Elborn JS. Detection of anaerobic bacteria in high numbers in sputum from patients with Cystic Fibrosis. *Am J Respir Dis Crit Care Med*. 2008; 177(9):995-1001
58. Lorenz E, **Muhlebach MS**, Tessier PA, Alexis NE, Hite RD, Seeds MC, Peden DP. Different expression ratio of s100A8/A9 and s100A12 in acute and chronic Lung diseases. *Respiratory Medicine* 2008; 102(4):567-573.
59. **Muhlebach MS**, MacDonald SL, Button B, Hubbard JJ, Turner ML, Boucher RC, Kilpatrick DC. Association between mannan-binding lectin and impaired lung function in cystic fibrosis may be age dependent. *Clin Exp Immunol*. 2006; 145:302-327.

60. Alexis NE, **Muhlebach MS**, Peden DB, Noah TL. Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. *J Cystic Fibrosis* 2006;5:17-25
61. **Muhlebach, MS**, Miller MB, Moore C, Wedd JP, Drake AF, Leigh MW. Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis? *Ped. Pulm.* 2006; 41;445-451
62. Becker MN, Sauer MS, **Muhlebach MS**, Hirsh AJ, Wu Q, Verghese MW, Randell SH. Cytokine secretion by cystic fibrosis airway epithelial cells. *Am J Respir Dis Crit Care Med.* 2004;169: 645-653.
63. **Muhlebach-Sponer M**, Reed B, Noah TL. Quantitative cytokine gene expression in cystic fibrosis airway. *Ped Pulm.* 2004; 37:393-399.
64. **Muhlebach-Sponer M**, Noah TL. Endotoxin activity and inflammatory markers in the airways of young cystic fibrosis patients. *Am J Respir Dis Crit Care Med.* 2002;165:911-915.
65. Kazachkov MY, **Muhlebach-Sponer M**, Livasy CA, Noah TL. Lipid laden macrophage index and inflammation in BALF. *Eur Respir J.* 2001;18;790-795.
66. **Muhlebach-Sponer M**, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. *Am J Respir Dis Crit Care Med.* 1999; 160:186-191.
67. **Muhlebach-Sponer M**, Zbinden R, da Silva VA, Gnehm HP. Intrathecal rubella antibodies in an adolescent with Guillain-Barré syndrome after mumps-measles-rubella vaccination. *European J. of Pediatrics* 1995; 154: 166.
68. Ghio A, Roggli VL, Soukup JM, Richards JH, Randell SH, **Muhlebach MS**. Iron accumulates in the lavage and explanted lungs of cystic fibrosis patients. *J Cystic Fibrosis* 2012 doi:pii: S1569-1993(12)00202-0
69. **Sponer M**, Nick HP, Schnebli HP. Different susceptibility of elastase inhibitors to inactivation by proteinases from *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *Biol Chem Hoppe-Seyler* 1991; 372: 963-970.